158 related articles for article (PubMed ID: 27824760)
1. Prevalence of Human Papillomavirus in Self-Collected Cervicovaginal Swabs in Young Women in the United States Between 2003 and 2012.
Tarney CM; Klaric J; Beltran T; Pagan M; Han J
Obstet Gynecol; 2016 Dec; 128(6):1241-1247. PubMed ID: 27824760
[TBL] [Abstract][Full Text] [Related]
2. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.
Markowitz LE; Hariri S; Lin C; Dunne EF; Steinau M; McQuillan G; Unger ER
J Infect Dis; 2013 Aug; 208(3):385-93. PubMed ID: 23785124
[TBL] [Abstract][Full Text] [Related]
3. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of HPV After Introduction of the Vaccination Program in the United States.
Markowitz LE; Liu G; Hariri S; Steinau M; Dunne EF; Unger ER
Pediatrics; 2016 Mar; 137(3):e20151968. PubMed ID: 26908697
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States--National Health And Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact?
Dunne EF; Sternberg M; Markowitz LE; McQuillan G; Swan D; Patel S; Unger ER
J Infect Dis; 2011 Aug; 204(4):562-5. PubMed ID: 21791658
[TBL] [Abstract][Full Text] [Related]
6. Change in Human Papillomavirus Prevalence Among U.S. Women Aged 18-59 Years, 2009-2014.
Berenson AB; Hirth JM; Chang M
Obstet Gynecol; 2017 Oct; 130(4):693-701. PubMed ID: 28885413
[TBL] [Abstract][Full Text] [Related]
7. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.
Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(12):415-420. PubMed ID: 33764964
[TBL] [Abstract][Full Text] [Related]
8. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
9. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
Oliver SE; Unger ER; Lewis R; McDaniel D; Gargano JW; Steinau M; Markowitz LE
J Infect Dis; 2017 Sep; 216(5):594-603. PubMed ID: 28931217
[TBL] [Abstract][Full Text] [Related]
11. Fall in human papillomavirus prevalence following a national vaccination program.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Cummins E; Liu B; Bateson D; McNamee K; Garefalakis M; Garland SM
J Infect Dis; 2012 Dec; 206(11):1645-51. PubMed ID: 23087430
[TBL] [Abstract][Full Text] [Related]
12. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of HPV infection among females in the United States.
Dunne EF; Unger ER; Sternberg M; McQuillan G; Swan DC; Patel SS; Markowitz LE
JAMA; 2007 Feb; 297(8):813-9. PubMed ID: 17327523
[TBL] [Abstract][Full Text] [Related]
14. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.
Covert C; Ding L; Brown D; Franco EL; Bernstein DI; Kahn JA
Hum Vaccin Immunother; 2019; 15(7-8):1962-1969. PubMed ID: 30633598
[TBL] [Abstract][Full Text] [Related]
15. Tobacco Use and Prevalence of Human Papillomavirus in Self-Collected Cervicovaginal Swabs Between 2009 and 2014.
Tarney CM; Beltran TA; Klaric J; Han JJ
Obstet Gynecol; 2018 Jul; 132(1):45-51. PubMed ID: 29889765
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
Guo F; Hirth JM; Berenson AB
Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
[TBL] [Abstract][Full Text] [Related]
18. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination.
Batmunkh T; Dalmau MT; Munkhsaikhan ME; Khorolsuren T; Namjil N; Surenjav U; Toh ZQ; Licciardi PV; Russell FM; Garland SM; Mulholland K; von Mollendorf C
Vaccine; 2020 Jun; 38(27):4316-4324. PubMed ID: 32387009
[TBL] [Abstract][Full Text] [Related]
19. Genital Human Papillomavirus Prevalence Over the Lifespan Among Females and Males in a National Cross-Sectional Survey, United States, 2013-2016.
Lewis RM; Gargano JW; Unger ER; Querec TD; Markowitz LE
Sex Transm Dis; 2021 Nov; 48(11):855-863. PubMed ID: 34009919
[TBL] [Abstract][Full Text] [Related]
20. Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.
Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
Ann Intern Med; 2022 Jul; 175(7):918-926. PubMed ID: 35576590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
